Abbott Laboratories (ABT) is well-poised for growth in the coming quarters, driven by solid prospects in the core Diagnostics business. The raised 2023 outlook buoys optimism. However, forex woes and lower COVID sales impede growth. In the past six months, this Zacks Rank #3 (Hold) stock has gained 4.6% compared with 4.8% decline of the industry and a 7.8% rise of the S&P 500 composite. This renowned provider of a diversified line of healthcare products has a market capitalization of $192.36 billion. The co ...